Trade Names:Neomycin Sulfate- Tablets 500 mg
Trade Names:Neo-fradin- Oral solution 125 mg per 5 mL
Inhibits production of protein in bacteria, causing bacterial cell death.
Poorly absorbed from the GI tract (3%).
Small amount absorbed is rapidly distributed to the tissues. Removed by dialysis.
Small fraction absorbed is eliminated by the kidney. The unabsorbed portion (97%) is eliminated unchanged in the feces.
As adjunctive treatment for suppression of normal bacterial flora of the bowel (tablet); as adjunctive therapy in hepatic coma to reduce ammonia-forming bacteria in the intestinal tract (tablet and solution).
Patients with intestinal obstruction; inflammatory or ulcerative GI disease; history of sensitivity to aminoglycosides or any component of the product.
PO 4 to 12 g/day in divided doses. Treatment should be continued over a period of 5 to 6 days.Preoperative ProphylaxisAdults
PO As part of a bowel preparation regimen, 1 g of neomycin and 1 g of erythromycin are given orally on pre-op day 1 at 1 PM, 2 PM, and 11 PM.
Store tablets at controlled room temperature (68° to 77°F). Store oral solution at controlled room temperature (59° to 86°F).
Neomycin ototoxicity or nephrotoxicity may be enhanced.Anticoagulants (eg, warfarin)
May increase the anticoagulant effects by decreasing vitamin K availability.Digoxin, fluorouracil, methotrexate, penicillin V, vitamin B-12
Intestinal absorption of these agents may be inhibited by neomycin.Potent diuretics (eg, ethacrynic acid, furosemide)
When administered IV, diuretics may enhance neomycin toxicity by altering the concentration in serum and tissue.
None well documented.
Nausea; vomiting; diarrhea.
Systemic absorption of neomycin occurs after oral administration, and toxic reactions may occur (eg, ototoxicity, nephrotoxicity). Neuromuscular blockade and respiratory paralysis have been reported. The risk of toxicity may be increased by dehydration or advanced age.
Category D .
Safety and efficacy not established.
If renal insufficiency develops during oral therapy, consider reducing the neomycin dose or discontinuing therapy.
Use with caution in patients with muscular disorders (eg, myasthenia gravis, parkinsonism) because neomycin may aggravate muscle weakness.
Prolonged or repeated use may result in bacterial or fungal overgrowth of nonsusceptible organisms and secondary infections.
Bile acid fecal excretion may be increased.
Risk may continue after drug withdrawal.
Intestinal lactase activity may be reduced.
Oral neomycin (12 g/day) produces malabsorption of a variety of substances including fat, nitrogen, cholesterol, carotene, glucose, xylose, lactose, sodium, calcium, cyanocobalamin, and iron.
Neurotoxicity, ototoxicity, nephrotoxicity.
Copyright © 2009 Wolters Kluwer Health.